# Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

> **NCT05506969** · PHASE2 · COMPLETED · sponsor: **Dynavax Technologies Corporation** · enrollment: 200 (actual)

## Conditions studied

- Plague, Pneumonic
- Plague
- Vaccine-Preventable Diseases

## Interventions

- **BIOLOGICAL:** rF1V-1018
- **BIOLOGICAL:** rF1V vaccine

## Key facts

- **NCT ID:** NCT05506969
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-09
- **Primary completion:** 2023-10-03
- **Final completion:** 2024-04-26
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05506969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05506969, "Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05506969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*